Science you can see. Beauty you can feel.
Myobloc RimabotulinumtoxinB
Botulinum Toxin Type B - Only FDA-Approved Type B - Solstice Neurosciences

Buy Myobloc Wholesale NYC

RimabotulinumtoxinB | Wholesale Per Vial

From $312.00 / vial

4.8 / 5.0 - 187 reviews

Select Products

Myobloc RimabotulinumtoxinB 2,500 U/mL VialWholesale price per vial
$312.00
0
Myobloc RimabotulinumtoxinB 5,000 U/mL VialWholesale price per vial
$468.00
0
Myobloc RimabotulinumtoxinB 10,000 U/mL VialWholesale price per vial
$880.00
0
Your Selection
Order Total$0.00

The world's only FDA-approved botulinum toxin Type B - the essential alternative for Type A-resistant patients with cervical dystonia and therapeutic indications

Myobloc (RimabotulinumtoxinB) is the only commercially available botulinum toxin type B, manufactured by Solstice Neurosciences. Unlike all other FDA-approved neurotoxins that use the type A serotype, Myobloc acts on a different receptor subtype (SNARE protein VAMP/synaptobrevin) with a distinct mechanism of action. This makes it invaluable for patients who have developed neutralizing antibodies to botulinum toxin type A products, or who require an alternative toxin for therapeutic cervical dystonia management.

  • Only FDA-approved botulinum toxin Type B - unique serotype and mechanism
  • Essential for Type A-resistant patients - distinct receptor binding profile
  • Ready-to-use liquid formulation - no reconstitution required
Delivery
Fast Tracked Priority
Sourcing
USA Genuine Products
Support
Friendly Customer Care
Find a Specialist Near You

Also see: All Neurotoxins | Official info: Myobloc.com

The Only FDA-Approved Botulinum Toxin Type B

Myobloc (RimabotulinumtoxinB) occupies a unique and clinically irreplaceable position in the neurotoxin market. As the sole FDA-approved botulinum toxin Type B, it cleaves VAMP/synaptobrevin - a different SNARE complex protein than the SNAP-25 target of all Type A toxins. This distinct mechanism means Myobloc retains full efficacy in patients who have developed neutralizing antibodies to type A formulations.

Myobloc is FDA-approved for the treatment of cervical dystonia and is supplied as a ready-to-use liquid - no reconstitution required, unlike all type A products that arrive as lyophilized powders. Its lower pH (approximately 5.6) contributes to greater autonomic effects, which practitioners factor into their dosing protocols for therapeutic indications.

Key Differentiators

  • 01Only FDA-approved botulinum toxin Type B - unique SNARE complex target
  • 02Ready-to-use liquid formulation - no reconstitution required at point of care
  • 03Essential alternative for Type A-resistant patients with neutralizing antibodies
  • 04Faster onset than Type A - effects begin within 24-48 hours
  • 05Available in three vial concentrations for precise therapeutic dosing flexibility

Product Specifications

Product NameMyobloc
Active IngredientRimabotulinumtoxinB (Botulinum Toxin Type B)
Vial Sizes2,500 U/mL - 5,000 U/mL - 10,000 U/mL
ManufacturerSolstice Neurosciences / US WorldMeds
FDA Approval2000 (cervical dystonia)
Onset of Action24-48 hours
Duration12-16 weeks typical
FormulationReady-to-use liquid (no reconstitution needed)

Results Timeline

24-48 Hours

Faster onset than Type A products - initial muscle relaxation and symptom relief begin within the first two days post-injection.

Week 2

Full effect established - optimal muscle relaxation and symptomatic improvement in cervical dystonia achieved.

Weeks 12-16

Results typically maintained for 12-16 weeks, at which point retreatment may be indicated based on clinical assessment.

Current Pricing

Wholesale prices listed per vial.

Myobloc RimabotulinumtoxinB 2,500 U/mL VialWholesale price per vial
$312.00
Myobloc RimabotulinumtoxinB 5,000 U/mL VialWholesale price per vial
$468.00
Myobloc RimabotulinumtoxinB 10,000 U/mL VialWholesale price per vial
$880.00

Pricing is subject to change. For licensed practitioners only.

Step 1: Patient Assessment and Antibody Evaluation

For patients presenting with secondary non-response to Type A products, the practitioner evaluates neutralizing antibody status. Myobloc is indicated when Type A resistance is confirmed or clinically suspected, providing a true alternative with a fully distinct mechanism.

Step 2: Ready-to-Use Administration

Unlike Type A toxins requiring reconstitution, Myobloc is drawn directly from the vial and injected into affected cervical muscles. The liquid formulation eliminates preparation time and reconstitution variability - a practical benefit in high-volume clinical settings.

Step 3: Type B Neuromuscular Blockade

RimabotulinumtoxinB cleaves VAMP/synaptobrevin, a key vesicle-associated membrane protein required for acetylcholine exocytosis. This targets a different SNARE complex protein than SNAP-25 (cleaved by all Type A toxins), resulting in complete functional efficacy in Type A-resistant patients.

Step 4: Clinical Response and Monitoring

Effects begin within 24-48 hours and peak at approximately 2 weeks. Duration typically ranges 12-16 weeks. For cervical dystonia management, retreatment at 12-week intervals is common clinical practice.

Who Is Myobloc Right For?

Myobloc is the essential option for patients with cervical dystonia who have developed secondary resistance to Type A botulinum toxin products. Because it acts on a distinct molecular target, it retains full clinical efficacy when all Type A neurotoxins have become ineffective due to neutralizing antibody formation.

In neurological and movement disorder clinics, Myobloc fills a genuinely irreplaceable role. For the broader aesthetic market, it may also be considered off-label by experienced injectors for patients who have exhausted Type A options and still desire muscle relaxation outcomes.

Ideal Candidates

  • ?Patients with cervical dystonia and confirmed Type A resistance
  • ?Practitioners seeking an alternative when Type A products are contraindicated
  • ?Clinical settings that require ready-to-use neurotoxin without reconstitution steps

Not Recommended For

  • -Individuals with known hypersensitivity to botulinum toxin or product excipients
  • -Patients with dysphagia risk - Type B has higher autonomic side effect profile
  • -Pregnant or breastfeeding women
  • -Patients with pre-existing neuromuscular conditions (myasthenia gravis, ALS)

A consultation with a licensed Sculptra NYC specialist is required. See Important Safety Information below.

Myobloc is a botulinum toxin Type B, while Botox, Dysport, Xeomin, Daxxify, Letybo, and Jeuveau are all Type A. They cleave different proteins in the SNARE complex - Type A cleaves SNAP-25; Type B cleaves VAMP/synaptobrevin. This means Myobloc retains full efficacy in patients with Type A neutralizing antibodies. Myobloc is also a ready-to-use liquid, whereas all Type A products require reconstitution from a lyophilized powder.

Myobloc is FDA-approved only for cervical dystonia (therapeutic). Off-label cosmetic use has been reported in the literature, but it is less common than Type A products due to its higher autonomic side effect profile (dry mouth, dry eyes) at higher doses. Experienced practitioners may use it off-label when Type A resistance is present.

The most common adverse events include dry mouth (dysphagia), injection site pain, headache, neck pain, and dysphagia. The autonomic effects (dry mouth, dry eyes) are more pronounced with Type B than Type A, and are dose-dependent. Most events are mild and transient.

Myobloc should be stored refrigerated at 2-8C (36-46F). Once removed from refrigeration, it can be stored at room temperature for up to 4 hours. Unlike lyophilized Type A products, Myobloc does not require reconstitution and should not be frozen.

No. Myobloc units are NOT interchangeable with any Type A botulinum toxin. The unit systems are completely different - Myobloc uses much higher numerical unit counts (2,500-10,000 U/mL) compared to Type A products (50-200 U/vial). Practitioners must refer to Myobloc-specific dosing tables. Never convert units between serotypes.

You May Also Like
Botox Cosmetic OnabotulinumtoxinA
Botulinum Toxin Type A

Botox Cosmetic
OnabotulinumtoxinA - Allergan

The gold standard - 20+ years of proven safety and precision results

From $267.00 / vial

View DetailsOrder Now
[Image: Letybo- 50U Vial]
Newest FDA-Approved Toxin

Letybo
LetbotulinumtoxinA - Hugel

The latest FDA-approved neurotoxin - Korean-engineered precision

From $239.00 / vial

View DetailsOrder Now
[Image: Daxxify- 100U Vial]
Long-Duration Neurotoxin

Daxxify
DaxibotulinumtoxinA - Revance

Longest-lasting FDA-approved neurotoxin - 6+ months clinical results

From $349.00 / vial

View DetailsOrder Now

Important Safety Information

INDICATIONS: Myobloc (rimabotulinumtoxinB) is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

CONTRAINDICATIONS: Myobloc is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any component of the formulation.

WARNINGS AND PRECAUTIONS - DISTANT SPREAD OF TOXIN EFFECT: Postmarketing reports indicate effects may spread from the area of injection. Swallowing and breathing difficulties can be life-threatening. The risk is greatest at higher doses. Units of Myobloc are NOT interchangeable with other botulinum toxin products - do not convert units between serotypes.

MOST COMMON ADVERSE REACTIONS: Dry mouth, dysphagia, dyspepsia, injection site pain, headache, neck pain. Autonomic effects (dry mouth, dry eyes) are more frequent with Type B than Type A products.

References: 1. Myobloc US Prescribing Information, US WorldMeds, 2023. 2. FDA BLA 103846.